ArticleThe ultrasound journal2025
Application of three-dimensional Superb micro-vascular imaging (3D-SMI) combined with quantitative blood flow analysis in the noninvasive diagnosis of renal tumors.
Article in The ultrasound journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the diagnostic value of three-dimensional superb micro-vascular imaging (3D-SMI) combined with quantitative analysis of Area and VI in differentiating benign and malignant renal tumors.
methodsA total of 256 renal lesions from 254 patients who underwent gray-scale ultrasound (Gray US), two-dimensional superb micro-vascular imaging (2D-SMI), and 3D-SMI examinations at Tianjin Medical University Cancer Institute and Hospital between January 2022 and June 2024 were retrospectively analyzed. The imaging features on Gray US, 2D-SMI and 3D-SMI were recorded. Based on 3D-SMI, Vascular Architecture were classified into five types: Type I (avascular), Type II (spotty flow), Type III (sparse flow), Type IV (encircling), and Type V (rich flow). The plane with the most abundant blood flow was selected, and the Area and VI were calculated using Image Pro Plus (IPP) software. Histopathology from surgery or biopsy served as the reference standard. The differences in Vascular Architecture, Area, and VI between benign and malignant renal tumors were compared, and their diagnostic performance was evaluated.
resultsAmong the 256 lesions, 70 were benign and 186 were malignant. The interobserver agreement for Vascular Architecture classification was good (Kappa = 0.803), and the consistency for Area and VI was high (ICC = 0.835 and 0.864, respectively). Benign tumors Vascular Architecture were mainly type II or III, with mean Area and VI values of 945.87 ± 568.26 (range: 68-3125) and 5.93 ± 4.95 (range: 0.23-24.73), respectively. Malignant tumors were predominantly type IV or V, with mean Area and VI values of 3694.53 ± 2612.38 (range: 93-9965) and 18.21 ± 10.83 (range: 0.69-48.13), respectively. Significant differences were observed in Vascular Architecture, Area, and VI between benign and malignant lesions (all P < 0.001). The area under the ROC curve (AUC) values for 3D-SMI Vascular Architecture, Area, VI, 2D-SMI, and Gray US were 0.813, 0.807, 0.859, 0.750, and 0.718, respectively. VI demonstrated the highest diagnostic performance, with a cutoff value of 8.19 (sensitivity: 82.26%; specificity: 85.51%). Among benign subtypes, there were no significant differences in Vascular Architecture or Area (P > 0.05), while the VI of oncocytoma was significantly higher than epithelioid angiomyolipoma (EMAL), metanephric adenomas (MA), and angiomyolipoma (AML)(P < 0.01). Among malignant subtypes, clear cell renal cell carcinoma (ccRCC) showed distinct Vascular Architecture compared with papillary renal cell carcinoma(pRCC), chromophobe renal cell carcinoma(chRCC), and Xp11.2 translocation/TFE3 fusion-associated renal cell carcinoma(tRCC) (P < 0.01). The Area and VI of ccRCC were significantly higher than those of pRCC and chRCC (P < 0.05), but not significantly different from tRCC (P > 0.05).
conclusion3D-SMI provides three-dimensional visualization of Vascular Architecture. Quantitative analysis of the most vascularized plane using Area and VI differentiation between benign and malignant renal tumors, with VI demonstrating the best diagnostic efficacy. This technique offers a non-invasive diagnostic approach for renal tumors.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.